293 related articles for article (PubMed ID: 31313044)
1. Completion of Adjuvant Chemotherapy After Upfront Surgical Resection for Pancreatic Cancer Is Uncommon Yet Associated With Improved Survival.
Altman AM; Wirth K; Marmor S; Lou E; Chang K; Hui JYC; Tuttle TM; Jensen EH; Denbo JW
Ann Surg Oncol; 2019 Nov; 26(12):4108-4116. PubMed ID: 31313044
[TBL] [Abstract][Full Text] [Related]
2. Beyond the dollar: Influence of sociodemographic marginalization on surgical resection, adjuvant therapy, and survival in patients with pancreatic cancer.
Kagedan DJ; Abraham L; Goyert N; Li Q; Paszat LF; Kiss A; Earle CC; Mittmann N; Coburn NG
Cancer; 2016 Oct; 122(20):3175-3182. PubMed ID: 27391466
[TBL] [Abstract][Full Text] [Related]
3. Time to the initiation of adjuvant chemotherapy does not impact survival in patients with resected pancreatic cancer.
Mirkin KA; Greenleaf EK; Hollenbeak CS; Wong J
Cancer; 2016 Oct; 122(19):2979-87. PubMed ID: 27328270
[TBL] [Abstract][Full Text] [Related]
4. Survival benefit of neoadjuvant therapy in patients with non-metastatic pancreatic ductal adenocarcinoma: A propensity matching and intention-to-treat analysis.
Sugimoto M; Takahashi N; Farnell MB; Smyrk TC; Truty MJ; Nagorney DM; Smoot RL; Chari ST; Carter RE; Kendrick ML
J Surg Oncol; 2019 Nov; 120(6):976-984. PubMed ID: 31452208
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant therapy versus upfront surgery for early-stage left-sided pancreatic adenocarcinoma: A propensity-matched analysis from a national cohort of distal pancreatectomies.
Nassour I; Adam MA; Kowalsky S; Al Masri S; Bahary N; Singhi AD; Lee K; Zureikat A; Paniccia A
J Surg Oncol; 2021 Jan; 123(1):245-251. PubMed ID: 33103242
[TBL] [Abstract][Full Text] [Related]
6. Type of Resection (Whipple vs. Distal) Does Not Affect the National Failure to Provide Post-resection Adjuvant Chemotherapy in Localized Pancreatic Cancer.
Bergquist JR; Ivanics T; Shubert CR; Habermann EB; Smoot RL; Kendrick ML; Nagorney DM; Farnell MB; Truty MJ
Ann Surg Oncol; 2017 Jun; 24(6):1731-1738. PubMed ID: 28070725
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant chemotherapy is associated with improved survival in patients with left-sided pancreatic adenocarcinoma.
Ocuin LM; Hardacre JM; Ammori JB; Rothermel LD; Mohamed A; Selfridge JE; Bajor D; Winter JM
J Surg Oncol; 2020 Dec; 122(8):1595-1603. PubMed ID: 32844445
[TBL] [Abstract][Full Text] [Related]
8. Multi-agent neoadjuvant chemotherapy improves survival in early-stage pancreatic cancer: A National Cancer Database analysis.
Deng A; Wang C; Cohen SJ; Winter JM; Posey J; Yeo C; Basu Mallick A
Eur J Cancer; 2021 Apr; 147():17-28. PubMed ID: 33607382
[TBL] [Abstract][Full Text] [Related]
9. National Use of Chemotherapy in Initial Management of Stage I Pancreatic Cancer and Failure to Perform Subsequent Resection.
Ellis RJ; Ho JW; Schlick CJR; Merkow RP; Bentrem DJ; Bilimoria KY; Yang AD
Ann Surg Oncol; 2020 Mar; 27(3):909-918. PubMed ID: 31691112
[TBL] [Abstract][Full Text] [Related]
10. Impact of early disease progression and surgical complications on adjuvant chemotherapy completion rates and survival in patients undergoing the surgery first approach for resectable pancreatic ductal adenocarcinoma - A population-based cohort study.
Labori KJ; Katz MH; Tzeng CW; Bjørnbeth BA; Cvancarova M; Edwin B; Kure EH; Eide TJ; Dueland S; Buanes T; Gladhaug IP
Acta Oncol; 2016; 55(3):265-77. PubMed ID: 26213211
[TBL] [Abstract][Full Text] [Related]
11. A comparative analysis of survival outcomes between pancreatectomy and chemotherapy for elderly patients with adenocarcinoma of the pancreas.
Marmor S; Burke EE; Virnig BA; Jensen EH; Tuttle TM
Cancer; 2016 Nov; 122(21):3378-3385. PubMed ID: 27419382
[TBL] [Abstract][Full Text] [Related]
12. The Addition of Chemoradiation to Adjuvant Chemotherapy is Associated With Improved Survival Following Upfront Surgical Resection for Pancreatic Cancer With Nodal Metastases.
Altman AM; White MJ; Marmor S; Shukla D; Chang K; Lou E; LaRocca CJ; Hui JYC; Tuttle TM; Jensen EH; Denbo JW
Cancer Control; 2022; 29():10732748221109991. PubMed ID: 35839251
[TBL] [Abstract][Full Text] [Related]
13. Five-Year Actual Overall Survival in Resected Pancreatic Cancer: A Contemporary Single-Institution Experience from a Multidisciplinary Perspective.
Picozzi VJ; Oh SY; Edwards A; Mandelson MT; Dorer R; Rocha FG; Alseidi A; Biehl T; Traverso LW; Helton WS; Kozarek RA
Ann Surg Oncol; 2017 Jun; 24(6):1722-1730. PubMed ID: 28054192
[TBL] [Abstract][Full Text] [Related]
14. The addition of chemoradiation to adjuvant chemotherapy is associated with improved survival in lymph node-positive gastric cancer.
Altman AM; Sheka AC; Marmor S; Lou E; Reynolds M; Hui JYC; Tuttle TM; Jensen EH; Denbo JW
Surg Oncol; 2020 Sep; 34():134-139. PubMed ID: 32891318
[TBL] [Abstract][Full Text] [Related]
15. A single center experience in resectable pancreatic ductal adenocarcinoma : the limitations of the surgery-first approach. Critical review of the literature and proposals for practice update.
Dumont R; Puleo F; Collignon J; Meurisse N; Chavez M; Seidel L; Gast P; Polus M; Loly C; Delvenne P; Meunier P; Hustinx R; Deroover A; Detry O; Louis E; Martinive P; Van Daele D
Acta Gastroenterol Belg; 2017; 80(4):451-461. PubMed ID: 29560639
[TBL] [Abstract][Full Text] [Related]
16. Extended neoadjuvant chemotherapy for borderline resectable pancreatic cancer demonstrates promising postoperative outcomes and survival.
Rose JB; Rocha FG; Alseidi A; Biehl T; Moonka R; Ryan JA; Lin B; Picozzi V; Helton S
Ann Surg Oncol; 2014 May; 21(5):1530-7. PubMed ID: 24473642
[TBL] [Abstract][Full Text] [Related]
17. Optimal Adjuvant Treatment Approach After Upfront Resection of Pancreatic Cancer: Revisiting the Role of Radiation Based on Pathologic Features.
Moaven O; Clark CJ; Russell GB; Votanopoulos KI; Howerton R; Levine EA; Shen P
Ann Surg; 2021 Dec; 274(6):1058-1066. PubMed ID: 31913868
[TBL] [Abstract][Full Text] [Related]
18. Overall survival is increased among stage III pancreatic adenocarcinoma patients receiving neoadjuvant chemotherapy compared to surgery first and adjuvant chemotherapy: An intention to treat analysis of the National Cancer Database.
Shubert CR; Bergquist JR; Groeschl RT; Habermann EB; Wilson PM; Truty MJ; Smoot RL; Kendrick ML; Nagorney DM; Farnell MB
Surgery; 2016 Oct; 160(4):1080-1096. PubMed ID: 27522556
[TBL] [Abstract][Full Text] [Related]
19. Is Neoadjuvant Therapy Sufficient in Resected Pancreatic Cancer Patients? A National Study.
de Geus SWL; Kasumova GG; Eskander MF; Ng SC; Kent TS; James Moser A; Vahrmeijer AL; Callery MP; Tseng JF
J Gastrointest Surg; 2018 Feb; 22(2):214-225. PubMed ID: 29235000
[TBL] [Abstract][Full Text] [Related]
20. Clinical Impact of Neoadjuvant Chemotherapy and Chemoradiotherapy in Borderline Resectable Pancreatic Cancer: Analysis of 884 Patients at Facilities Specializing in Pancreatic Surgery.
Nagakawa Y; Sahara Y; Hosokawa Y; Murakami Y; Yamaue H; Satoi S; Unno M; Isaji S; Endo I; Sho M; Fujii T; Takishita C; Hijikata Y; Suzuki S; Kawachi S; Katsumata K; Ohta T; Nagakawa T; Tsuchida A
Ann Surg Oncol; 2019 Jun; 26(6):1629-1636. PubMed ID: 30610555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
